LEGN
Legend Biotech Corporation · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -7.7% ·
share flow -20.5% ·
net new positions -8.3%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 92 | +12 | 61.78M | $1.78B | +17 | −5 |
| Q1 2026 | 82 | -3 | 51.41M | $929.52M | +5 | −8 |
| Q4 2025 | 86 | +2 | 50.21M | $1.09B | +2 | — |
| Q3 2025 | 13 | -2 | 38.53M | $1.26B | — | −2 |
| Q2 2025 | 12 | -1 | 34.51M | $1.22B | +1 | −2 |
| Q1 2025 | 10 | 0 | 13.38M | $453.85M | — | — |
| Q4 2024 | 10 | -1 | 15.80M | $514.13M | — | −1 |
| Q3 2024 | 10 | +3 | 16.52M | $804.74M | +3 | — |
| Q2 2024 | 7 | — | 18.35M | $812.58M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 25.67M | — | $911.04M | 0.1% | n/c | 1 | SEC ↗ ×7 |
| 2 | BlackRock ✦ (passive) | 4.25M | — | $150.78M | 0.0% | n/c | 1 | SEC ↗ ×17 |
| 3 | State Street Global Advisors ✦ (passive) | 1.12M | -1.6% | $39.74M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 800.22K | -88.1% | $28.40M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 5 | Millennium Management ✦ | 740.85K | -13.7% | $26.29M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 656.30K | -7.7% | $23.29M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 473.74K | -9.4% | $16.66M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 8 | Two Sigma Investments ✦ | 269.70K | -66.4% | $9.57M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 9 | Point72 Asset Management ✦ | 227.91K | New | $8.09M | 0.0% | New | 1 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 165.06K | +6.4% | $5.86M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 11 | The Vanguard Group ✦ (passive) | 122.03K | — | $4.33M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 12 | Marshall Wace ✦ | 13.68K | -96.4% | $485,610 | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $8.09M | 0.0% |
Exited
| Wellington Management | $63.02M | was 0.0% |
| Bridgewater Associates | $7.65M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 189 holders, 95.78M shares, $1.69B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 27.37K sh · $258,920
Officer · 5.43K sh · $49,630
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology